Literature DB >> 12496418

Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.

Masafumi Nakayama1, Kazumi Ishidoh, Yuko Kojima, Norihiro Harada, Eiki Kominami, Ko Okumura, Hideo Yagita.   

Abstract

TWEAK, a TNF family member, is produced by IFN-gamma-stimulated monocytes and induces multiple pathways of cell death, including caspase-dependent apoptosis, cathepsin B-dependent necrosis, and endogenous TNF-alpha-mediated cell death, in a cell type-specific manner. However, the TWEAK receptor(s) that mediates these multiple death pathways remains to be identified. Recently, fibroblast growth factor-inducible 14 (Fn14) has been identified to be a TWEAK receptor, which was responsible for TWEAK-induced proliferation of endothelial cells and angiogenesis. Because Fn14 lacks the cytoplasmic death domain, it remains unclear whether Fn14 can also mediate the TWEAK-induced cell death. In this study, we demonstrated that TWEAK could induce apoptotic cell death in Fn14 transfectants. A pan-caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, rather sensitized the Fn14 transfectants to TWEAK-induced cell death by necrosis via reactive oxygen intermediates and cathepsin B-dependent pathway. By using newly generated agonistic anti-Fn14 mAbs, we also observed that Fn14 is constitutively expressed on the cell surface of all TWEAK-sensitive tumor cell lines, and can transmit the multiple death signals. Moreover, an anti-Fn14 mAb that blocks TWEAK-Fn14 interaction could totally abrogate TWEAK binding and TWEAK-induced cell death in all TWEAK-sensitive tumor cell lines. These results revealed that the multiple pathways of TWEAK-induced cell death are solely mediated by Fn14.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496418     DOI: 10.4049/jimmunol.170.1.341

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys.

Authors:  Tillmann Burghardt; Jürgen Kastner; Hani Suleiman; Eric Rivera-Milla; Natalya Stepanova; Claudio Lottaz; Marion Kubitza; Carsten A Böger; Sarah Schmidt; Mathias Gorski; Uwe de Vries; Helga Schmidt; Irmgard Hertting; Jeffrey Kopp; Anne Rascle; Markus Moser; Iris M Heid; Richard Warth; Rainer Spang; Joachim Wegener; Claudia T Mierke; Christoph Englert; Ralph Witzgall
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

2.  TWEAK induces liver progenitor cell proliferation.

Authors:  Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

3.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 4.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

5.  Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics.

Authors:  Yandong Nan; Faguang Jin; Shuanying Yang; Yingxuan Tian; Yonghong Xie; Enqing Fu; Hong Yu
Journal:  Med Oncol       Date:  2009-12-30       Impact factor: 3.064

6.  Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.

Authors:  Xiaoying Chen; Vahid Farrokhi; Pratap Singh; Mireia Fernandez Ocana; Jenil Patel; Lih-Ling Lin; Hendrik Neubert; Joanne Brodfuehrer
Journal:  MAbs       Date:  2017-11-30       Impact factor: 5.857

7.  Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura.

Authors:  T Chen; Z-P Guo; M-M Li; J-Y Li; X-Y Jiao; Y-H Zhang; H-J Liu
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

8.  Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.

Authors:  Ryo Yoriki; Satoru Akashi; Masayuki Sho; Takeo Nomi; Ichiro Yamato; Kiyohiko Hotta; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Kazuhiro Migita; Hideo Yagita; Yoshiyuki Nakajima
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

Review 9.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.